Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide

Area of Science:

• Immunology
• Molecular Biology
• Drug Discovery

Background:

• Interleukin-17A (IL-17A) is a pro-inflammatory cytokine central to autoimmune and inflammatory diseases.
• Current IL-17A inhibitors are monoclonal antibodies; an oral therapy is needed.

Purpose of the Study:

• To develop and characterize a novel, high-affinity peptide antagonist for IL-17A.
• To investigate the mechanism of IL-17A inhibition by the peptide antagonist.

Main Methods:

• Phage-display screening and optimization (saturation mutagenesis, amino acid substitutions) to identify a high-affinity IL-17A peptide antagonist (HAP).
• In vitro testing in primary human cells to assess HAP's efficacy in blocking inflammatory cytokine production.
• Crystal structure analysis to elucidate the binding mode of HAP to IL-17A and its receptor (IL-17RA).

Main Results:

• A 15-residue high-affinity IL-17A peptide antagonist (HAP) was identified.
• HAP specifically binds IL-17A, inhibiting its interaction with IL-17RA and blocking downstream inflammatory cytokine production in human cells.
• Structural studies revealed HAP binds symmetrically to IL-17A dimers, with N-terminal β-strands inserting between monomers and C-terminal α-helices blocking IL-17RA binding.

Conclusions:

• HAP represents a promising peptide antagonist for IL-17A, demonstrating potent inhibition of IL-17A signaling.
• The unique binding and inhibition mechanism of HAP provides a foundation for developing new oral peptide-based therapies against IL-17A.
• This study highlights opportunities for targeting challenging cytokines like IL-17A with peptide antagonists.